Eli Radiopharma

CNY 400.0M Series A

Announced: Nov 11, 2026
Sector: Biotechnology
Investors: 9

Summary

Eli Radiopharma completed a Series A financing of nearly RMB 400 million led by Huagai Capital. Eli Radiopharma is a radiopharmaceutical developer focused on oncology and neurological diseases.

Investors

Huagai Capital, Bayland Capital, Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management, Grand Flight Investment